Merge pull request #1481 from biolink/mbrush-patch-3

Update biolink-model.yaml

Author: sierra-moxon

biolink-model.yaml

@@ -3469,13 +3469,14 @@ slots:
       stabilize, or cure the condition or delay, prevent, or reduce the risk of it manifesting
       in the first place.
       ‘Treats’ edges should be asserted (knowledge_level: assertion) only in cases where there
-      is strong supporting evidence - i.e. the intervention is approved or in phase 4 trials for
-      the condition, or is an otherwise established treatment in the medical community (e.g. a
-      widely-accepted or formally recommended off-label use). In the absence of such evidence,
-      weaker predicates should be used in asserted edges (e.g. ‘in clinical trials for’ or
-      ‘beneficial in models of’). ‘Treats’ edges based on weaker or indirect forms of evidence
-      can however be created as predictions (knowledge_level: prediction) and should point to
-      the more foundational asserted edges that support them.
+      is strong supporting evidence - i.e. the intervention is approved for the condition, passed
+      phase 3 or in phase 4 trials for the condition, or is an otherwise established 
+      treatment in the medical community (e.g. a widely-accepted or formally recommended 
+      off-label use). In the absence of such evidence, weaker predicates should be used in 
+      asserted edges (e.g. ‘in clinical trials for’ or ‘beneficial in models of’). ‘Treats’ edges
+      based on weaker or indirect forms of evidence can however be created as predictions 
+      (knowledge_level: prediction) and should point to the more foundational asserted edges that 
+      support them.
     domain: chemical or drug or treatment
     range: disease or phenotypic feature
     annotations: